Lonigutamab

罗尼妥单抗

Report date: 2026/04/07 20:00:20

Base Information

Drug NameLonigutamab
Drug Alias NameVB-421
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionInsulin-like growth factor I receptor antagonists
TargetsInsulin-like growth factor I receptor
Therapy Area/IndicationsGraves Ophthalmopathy
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustralia
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesPierre Fabre Group
China Registration ClassN/A

Develop Information

Active CompaniesAlumis Inc
Inactive CompaniesValenzaBio Inc
Active IndicationsGraves Ophthalmopathy
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A